CSL Limited (ASX:CSL) and this ASX healthcare shares could be the ones to buy right now. Here’s what you need to know…
The post 2 ASX healthcare shares to buy next week appeared first on The Motley Fool Australia. –
One area of the share market that has been performing consistently well in recent years is the healthcare sector. Since this time in 2015, the S&P/ASX 200 Health Care index has generated a return of 122% for investors.
This has been underpinned by increasing demand, better technologies and treatments, and ageing populations.
Pleasingly, these tailwinds aren’t going away any time soon. In light of this, it is no surprise to learn that the sector has been tipped as a great place to invest over the 2020s.
But which healthcare shares should you buy? Here are two highly rated options:
CSL is one of the world’s leading biotherapeutics companies. It has been an exceptionally positive performer over the last decade thanks to a combination of acquisitions, its research and development (R&D) activities, growing plasma collection network, and its leading therapies. Its portfolio of therapies currently includes the likes of Privigen, Hizentra, Idelvion, and Afstyla. Though, this will be boosted further in the coming years thanks to its almost billion-dollar annual investment in R&D.
UBS appears confident that this strong form can continue. The broker recently retained its buy rating and $346.00 price target on the company’s shares. While it notes that plasma collection conditions are tough in some markets because of COVID-19, it remains positive on its outlook. Especially given how it has a range of options to mitigate this headwind and a burgeoning R&D pipeline.
Pro Medicus Limited (ASX: PME)
Pro Medicus is healthcare technology company that provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualisation solutions to healthcare organisations across the globe.
Due to the quality of its software, its sizeable market opportunity, and the shift away from legacy systems, Pro Medicus has been tipped to have a big future.
One broker that is positive on the company is Morgans. This month the broker retained its add rating and lifted its price target on the company’s shares to $35.02. It made the move after the company announced the signing of a five-year contract with MedStar Health worth a total of A$18 million.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
- 3 unstoppable ASX shares to buy
- 5 fantastic ASX shares to buy in 2021
- 2 of the best ASX healthcare shares to buy in 2021
- 3 top ASX shares to buy in 2021
- 7 top ASX biomedical shares in 2020
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.